Oncomed Pharmaceuticals (OMED) Sees Strong Trading Volume
Oncomed Pharmaceuticals Inc (NASDAQ:OMED) shares saw strong trading volume on Friday . 3,356,692 shares were traded during trading, an increase of 602% from the previous session’s volume of 478,194 shares.The stock last traded at $0.99 and had previously closed at $0.83.
Several research analysts have recently weighed in on the company. Zacks Investment Research downgraded Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. ValuEngine raised Oncomed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Wells Fargo & Co reaffirmed a “market perform” rating and set a $1.50 target price (down from $8.00) on shares of Oncomed Pharmaceuticals in a research note on Thursday, December 6th.
The company has a market capitalization of $32.45 million, a price-to-earnings ratio of -6.19 and a beta of 1.81.
COPYRIGHT VIOLATION WARNING: “Oncomed Pharmaceuticals (OMED) Sees Strong Trading Volume” was first posted by Marea Informative and is the property of of Marea Informative. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.mareainformativa.com/news/2019/03/17/oncomed-pharmaceuticals-omed-sees-strong-trading-volume.html.
About Oncomed Pharmaceuticals (NASDAQ:OMED)
OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway.
See Also: Insider Trading
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.